Breaking News Instant updates and real-time market news.

ITCI

Intra-Cellular

$15.50

0.49 (3.26%)

, GSK

GlaxoSmithKline

$35.06

-0.41 (-1.16%)

04:55
12/01/17
12/01
04:55
12/01/17
04:55

Leerink to hold a bus tour

11th Annual POLARxPRESS Bus Tour travels throughout the New York area visiting various pharmaceutical/healthcare companies on November 28-December 1.

ITCI

Intra-Cellular

$15.50

0.49 (3.26%)

GSK

GlaxoSmithKline

$35.06

-0.41 (-1.16%)

ACRS

Aclaris Therapeutics

$23.71

0.49 (2.11%)

ALKS

Alkermes

$52.29

0.84 (1.63%)

BGNE

BeiGene

$80.00

-2.99 (-3.60%)

ARDX

Ardelyx

$6.65

0.25 (3.91%)

ALNY

Alnylam

$134.54

6.4 (4.99%)

REGN

Regeneron

$361.86

3.23 (0.90%)

  • 09

    Dec

  • 14

    Dec

  • 25

    Mar

ITCI Intra-Cellular
$15.50

0.49 (3.26%)

11/09/17
RHCO
11/09/17
UPGRADE
Target $22
RHCO
Buy
Intra-Cellular upgraded to Buy at SunTrust on valuation
As previously reported, SunTrust analyst Edward Nash upgraded Intra-Cellular to Buy from Hold and kept his $22 price target. Nash says the outlook for FY18 has been conservative, adding that the recent pull-back in shares created a buying opportunity. The analyst is positive on the company's plans to file NDA for lumateperone in schizophrenia by mid-2018 as well as its three ongoing Phase III trials for bi-polar depression expected to fully enroll in FY18.
11/08/17
RHCO
11/08/17
UPGRADE
RHCO
Buy
Intra-Cellular upgraded to Buy from Hold at SunTrust
09/08/17
COWN
09/08/17
NO CHANGE
Target $27
COWN
Outperform
Intra-Cellular price target raised to $27 from $20 at Cowen
Cowen analyst Ritu Baral raised her price target on Intra-Cellular to $27 from $20 following the release of top-line Phase 3 switch data on the long-term safety of its lead drug lumateperone in schizophrenia. She is cautious on the meaningfulness of superior efficacy signals but sees them as solid evidence of maintenance of clinical control with lumateperone. Baral maintained her Outperform rating on Intra-Cellular shares.
09/07/17
09/07/17
UPGRADE
Target $33

Overweight
Intra-Cellular upgraded to Overweight after schizophrenia data at Piper Jaffray
As previously reported, Piper Jaffray analyst Charles Duncan upgraded Intra-Cellular to Overweight from Neutral after the company reported data from its "switching" study of lumateperone in schizophrenia outpatients on approved antipsychotics. He said the trial gives "some of the strongest evidence to date" that lumateperone is differentiated on a range of side effects from the current standard of care. Duncan raised his price target on Intra-Cellular to $33 from $14.
GSK GlaxoSmithKline
$35.06

-0.41 (-1.16%)

11/27/17
11/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch saying he views Lowe's shares as more attractive following the third quarter beat. 2. T-Mobile (TMUS) upgraded to Buy from Neutral at MoffettNathanson. 3. GlaxoSmithKline (GSK) upgraded to Buy from Neutral at UBS with analyst Michael Leuchten saying concerns of continuing earnings decline and the dividend sustainability are now overdone. 4. Ciena (CIEN) upgraded to Buy from Neutral at BofA/Merrill with analyst Tal Liani saying shares are at the low end of the historical range and the earnings growth profile is attractive. 5. Constellium (CSTM) upgraded to Outperform from Market Perform at Cowen with analyst Novid Russell saying the company's rapid deleveraging has allowed investors to focus on its significant growth projects, attractive end markets, and valuation discount relative to peers. Russell raised his price target to $13 from $11 on Constellium shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/24/17
DBAB
11/24/17
NO CHANGE
Target $59
DBAB
Hold
Deutsche cuts Merck target to $59 on competition from AbbVie, GSK
Deutsche Bank analyst Gregg Gilbert lowered his price target for Merck (MRK) to $59 from $62 citing expectations for more competitive pressure on Zepatier and Zostavax. The stock closed Wednesday up 10c to $54.37. Demand trends for Merck's hepatitis C virus drug Zepatier have continued to decline as AbbVie's (ABBV) Mavyret has gained traction, Gilbert told investors in a research note. The analyst also assumes "significant pressure" on Merck's shingles vaccine Zostavax from the near-term competitive launch of GlaxoSmithKline's (GSK) Shingrix. Gilbert views Merck's risk/reward as fairly balanced and he keeps a Neutral rating on the shares.
11/30/17
ARGS
11/30/17
NO CHANGE
Target $40
ARGS
Buy
GlaxoSmithKline price target lowered to $40 from $50 at Argus
Argus analyst John Eade lowered his price target on GlaxoSmithKline to $40 but kept his Buy rating, saying that the 10% decline in stock price over the past quarter presents a buying opportunity. Eade attributes the decline to the company lagging its peers in moving beyond the patent cliff as well as pricing pressure and generic threats to its respiratory blockbuster Advair/Seretide. However, the analyst says the new CEO should be able to accelerate the efforts to leverage the company's strengths, which include consumer products, vaccines and anti-infectives.
11/27/17
UBSW
11/27/17
UPGRADE
UBSW
Buy
GlaxoSmithKline upgraded to Buy from Neutral at UBS
UBS analyst Michael Leuchten upgraded GlaxoSmithKline to Buy with an unchanged price target of 1,550p. Concerns of continuing earnings decline and the dividend sustainability are now overdone, Leuchten tells investors in a research note. The analyst believes the dividend looks secure and views the 6% forecast yield as "handsome."
ACRS Aclaris Therapeutics
$23.71

0.49 (2.11%)

09/19/17
CANT
09/19/17
NO CHANGE
Target $50
CANT
Overweight
Public FDA meeting positive for Aclaris, says Cantor
The FDA last Monday conducted a public meeting on alopecia areata patient-focused drug development, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. The meeting was constructive on alopecia as a disease and the need to get drugs approved, the analyst contends. She believes the meeting is a positive for Aclaris Therapeutics, which she notes is working on "several solutions to the problem." Chen has an Overweight rating on Aclaris with a $50 price target.
06/16/17
CANT
06/16/17
INITIATION
Target $50
CANT
Overweight
Aclaris Therapeutics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Aclaris Therapeutics with an Overweight rating and $50 price target.
04/26/17
LEER
04/26/17
NO CHANGE
Target $54
LEER
Outperform
Aclaris patent could be worth $15 per share, says Leerink
Leerink analyst Seamus Fernandez believes the A-101 patent announced today by Aclaris Therapeutics could add $15 per share to the company's net present value. The newly allowed patent expires in 2035, 11 years later than the analyst currently assumes loss of exclusivity in seborrheic keratosis. Extending the patent life of A-101 could increase the NPV contribution to $31 per share from $16, Fernandez tells investors in a research note. He keeps an Outperform rating on Aclaris with a $54 price target.
ALKS Alkermes
$52.29

0.84 (1.63%)

11/27/17
PIPR
11/27/17
NO CHANGE
PIPR
Overweight
Piper says Biogen strengthens MS franchise with 'reasonable' Alkermes deal
Piper Jaffray analyst Christopher Raymond said he sees the terms of Biogen's (BIIB) license and collaboration agreement to develop and commercialize Alkermes' (ALKS) ALKS 8700 as "reasonable" and he thinks the decision to in-license the drug makes sense and strengthens the Tecfidera franchise. Raymond maintains an Overweight rating on Biogen shares.
11/27/17
JEFF
11/27/17
NO CHANGE
Target $66
JEFF
Buy
Alkermes made prudent move selling ALKS 8700 rights, says Jefferies
Jefferies analyst Biren Amin thinks Alkermes (ALKS) made a prudent move by selling the rights of ALKS 8700 to Biogen (BIIB). The multiple sclerosis drug did not fit into the company's portfolio, Amin tells investors in an intraday research note. He believes Alkermes can now focus on programs such as ALKS-4230, an IL-2 for oncology. The analyst has a Buy rating on the shares with a $66 price target.
11/28/17
FBCO
11/28/17
NO CHANGE
Target $66
FBCO
Outperform
Alkermes agreement with Biogen should help monetize ALKS 8700, says Credit Suisse
Credit Suisse analyst Vamil Divan views Alkermes (ALKS) ALKS 8700 agreement with Biogen (BIIB) as a positive financial move for an underappreciated pipeline asset. The analyst notes that ALKS 8700 has not been given much credit by investors to date due to limited clinical data and patent uncertainty. Divan reiterates an Outperform rating and $66 price target on Alkermes shares.
11/28/17
BERN
11/28/17
NO CHANGE
Target $318
BERN
Outperform
Biogen price target raised to $318 from $310 at Bernstein
Bernstein analyst Aaron Gal raised his price target for Biogen (BIIB) to $318 from $310 after the company announced a licensing agreement with Alkermes (ALKS) to develop and commercialize ALKS 8700, a modified fumarate with a potentially differentiated GI tolerability profile. The analyst views this important improvement in Biogen's position in MS given the risk of generic Tecfidera. Further, Gal thinks the Street may be underappreciating the value of the asset. He reiterates an Outperform rating on Biogen's shares.
BGNE BeiGene
$80.00

-2.99 (-3.60%)

09/11/17
MAXM
09/11/17
NO CHANGE
MAXM
BeiGene data, Celgene deal closing positive, says Maxim
Maxim analyst Gabrielle Zhou says that preliminary data on a Phase 1/II trial of BeiGene's (BGNE) BGB-290 in patients with advanced solid tumors, including epithelial ovarian cancer, or EOC, showed that the drug has "a similar, if not superior anti-tumor effect compared to other PARP inhibitors in patients with EOC and other solid tumors." Zhou adds that the closing of the company's deal with Celgene (CELG) is also positive. The analyst raised her price target on BeiGene to $77 from $73 and keeps a Buy rating on the stock.
09/29/17
MAXM
09/29/17
NO CHANGE
MAXM
BeiGene price target raised to $120 from $77 at Maxim
Maxim analyst Gabrielle Zhou raised her price target on BeiGene after the company announced preliminary data from its ongoing Phase I/II study of BGBA317 in patients with solid tumors. The analyst says that the drug "has shown signals of efficacy in difficult to treat cancer types." She raised her out-year estimates for the drug and keeps a Buy rating on the stock.
11/14/17
BARD
11/14/17
DOWNGRADE
BARD
Neutral
BeiGene downgraded to Neutral from Outperform at Baird
11/14/17
BARD
11/14/17
DOWNGRADE
Target $83
BARD
Neutral
BeiGene downgraded to Neutral at Baird
As previously reported, Baird analyst Brian Skorney downgraded BeiGene to Neutral from Outperform. He continues to believe the lead assets are strong and that each is looking at a substantial commercial opportunity, but based on current valuation he is moving to the sidelines. Given the recent run-up, the stock already reflects a high probability of success for the company's assets, said Skorney, who raised his price target to $83 from $58 on BeiGene shares.
ARDX Ardelyx
$6.65

0.25 (3.91%)

10/12/17
CANT
10/12/17
NO CHANGE
Target $14
CANT
Ardelyx target raised to $14 on T3MPO-2 results at Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein raised her price target for Ardelyx to $14 saying the positive T3MPO-2 results in irritable bowel syndrome with constipation should allow the shares to regain lost ground. The data show a path to new drug application submission and a commercial opportunity above the current valuation, Goldstein tells investors in a research note. She reiterates an Overweight rating on Ardelyx.
10/17/17
LEER
10/17/17
INITIATION
Target $13
LEER
Outperform
Ardelyx reinitiated with an Outperform at Leerink
Leerink analyst Seamus Fernandez resumed coverage of Ardelyx with an Outperform rating and a $13 price target noting that in the last 9 months, the clinical profile of its lead asset tenapanor has been validated in three Phase 3 studies in two separate indications.
10/12/17
10/12/17
NO CHANGE
Target $19

Buy
Ardelyx price target raised to $19 after 'clean win' for tenapanor at Citi
As previously reported, Citi analyst Yigal Nochomovitz raised his price target on Ardelyx to $19 from $14 after the company's phase 3 trial of tenapanor in IBS-C resulted in a "clean win" by not only meeting its composite primary endpoint but also independently meeting both components of the primary endpoint and all secondary endpoints. The analyst raised his U.S. peak sales forecast for tenapanor in IBS-C to $320M from $270M and keeps a Buy rating on the stock, which is up 55% to $8.36 in morning trading.
10/12/17
SBSH
10/12/17
NO CHANGE
Target $19
SBSH
Buy
Ardelyx price target raised to $19 from $14 at Citi
ALNY Alnylam
$134.54

6.4 (4.99%)

11/08/17
LEHM
11/08/17
NO CHANGE
Target $158
LEHM
Overweight
Alnylam price target raised to $158 from $127 at Barclays
Barclays analyst Gena Wang raised her price target for Alnylam Pharmaceuticals to $158 saying the company highlighted multiple pipeline progresses during the Q3 earnings call. The analyst keeps an Overweight rating on the shares.
11/17/17
PIPR
11/17/17
NO CHANGE
Target $182
PIPR
Overweight
Piper trims Alnylam target to $182 after capital raise
Piper Jaffray analyst Edward Tenthoff trimmed his price target for Alnylam Pharmaceuticals to $182 from $188 to account for dilution from the company's issuance of 6.44M shares at $125. The company's cash position of $1.93B will allow for the patisiran launch and pipeline advancements, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Alnylam.
11/03/17
COWN
11/03/17
NO CHANGE
Target $151
COWN
Outperform
Alnylam price target raised to $151 from $117 at Cowen
Cowen analyst Ritu Baral raised her price target on Alnylam to $151 from $117 following its presentation of full data from the Phase 3 APOLLO trial of patisiran. The data showed benefits in cardiac measure and excellent safety and approval should be expected in 2018 with a broad label. Baral reiterated her Outperform rating on Alnylam shares.
11/09/17
JPMS
11/09/17
UPGRADE
Target $162
JPMS
Overweight
Alnylam upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Alnylam Pharmaceuticals saying he believes patisiran "has definitively solidified" a dominant market position in the ATTR amyloidosis space. The analyst expects a "smooth regulatory process" for patisiran and broad label enabling use in the mutant mixed FAC phenotype. Rama raised his price target for Alnylam shares to $162 from $86.
REGN Regeneron
$361.86

3.23 (0.90%)

11/28/17
BMOC
11/28/17
NO CHANGE
Target $444
BMOC
Market Perform
Regeneron price target lowered to $444 from $479 at BMO Capital
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron to $444, saying the Phase 2 trial failure of Eylea injection with Ang2 in AMD and DME "eliminates a potential growth source". The analyst notes that while the expectations for Ang2 were low, the setback is another example of long-term risks to Regeneron's core business. Luchini keeps his Market Perform rating, saying investors' focus now shifts to Praluent ODYSSEY outcomes data in early 2018, PANORAMA Phase III data of Eylea in diabetic retinopathy in the first half of next year, and updated Phase II data for REGN2810 in CSCC expected in the current quarter to be followed by potential filing in Q1 and proof-of-concept Phase I data for REGN3500.
11/13/17
MSCO
11/13/17
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees limited near-term impact on Regeneron from Novartis data
Morgan Stanley analyst Matthew Harrison noted that Novartis (NVS) presented RTH258 data at the American Academy of Ophthalmology meeting that did show the potential for a commercial "hook," namely an ability to "dry out" hard to treat patients. However, an FDA filing is not expected until the second half of 2018 and key safety details are still needed for a more accurate determination of brolucizumab's possible commercial impact, said Harrison, who sees limited near-term impact on Regeneron (REGN) from the data on the Eylea competitor. He keeps an Equal Weight rating on Regeneron shares.
11/16/17
EVER
11/16/17
NO CHANGE
Target $445
EVER
Outperform
Regeneron price target lowered to $445 from $605 at Evercore ISI
Evercore ISI lowered its price target for Regeneron (REGN) to $445 from $605 given meaningful competitive threat to Eylea. For every dollar of U.S. Eylea sales lost to competition, Regeneron has to make up for it with two times as much revenue from the Sanofi (SNY) JV, it adds. The firm has an Outperform rating on Regeneron's shares.
11/28/17
BOFA
11/28/17
NO CHANGE
BOFA
Equity Residential, Regeneron removed from US 1 List at BofA/Merrill

TODAY'S FREE FLY STORIES

03:05
12/14/17
12/14
03:05
12/14/17
03:05
General news
FX Action: USD-CAD ebbed to a six-day low »

FX Action: USD-CAD ebbed…

02:35
12/14/17
12/14
02:35
12/14/17
02:35
General news
FX Update: The dollar turned to consolidation »

FX Update: The dollar…

01:55
12/14/17
12/14
01:55
12/14/17
01:55
General news
FX Action: The USD index (DXY) fell 0.8% »

FX Action: The USD index…

23:00
12/13/17
12/13
23:00
12/13/17
23:00
General news
PBoC nudged rates higher »

PBoC nudged rates higher,…

LPSN

LivePerson

$11.05

-0.05 (-0.45%)

20:28
12/13/17
12/13
20:28
12/13/17
20:28
Initiation
LivePerson initiated at B. Riley FBR »

LivePerson initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HUSKF

Husky Energy

$12.42

-0.1177 (-0.94%)

20:26
12/13/17
12/13
20:26
12/13/17
20:26
Upgrade
Husky Energy rating change at Goldman Sachs »

Husky Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$51.68

-0.28 (-0.54%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Upgrade
ConocoPhillips rating change at Goldman Sachs »

ConocoPhillips upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

SAFM

Sanderson Farms

$167.64

0.64 (0.38%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DB

Deutsche Bank

$19.33

-0.05 (-0.26%)

19:17
12/13/17
12/13
19:17
12/13/17
19:17
Hot Stocks
DBNY, DBTCA raise prime lending rate to 4.5% from 4.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.04

-0.06 (-0.16%)

18:47
12/13/17
12/13
18:47
12/13/17
18:47
Hot Stocks
AT&T and Communications Workers of America reach tentative agreement »

AT&T Mobility has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$63.47

0.19 (0.30%)

18:33
12/13/17
12/13
18:33
12/13/17
18:33
Hot Stocks
Bristol-Myers granted exclusive license by Ono Pharma to develop ONO-4578 »

Bristol-Myers and Ono…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 05

    Mar

WFC

Wells Fargo

$59.40

-0.93 (-1.54%)

18:15
12/13/17
12/13
18:15
12/13/17
18:15
Hot Stocks
Breaking Hot Stocks news story on Wells Fargo »

Wells Fargo raises prime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

HBAN

Huntington Bancshares

$14.58

-0.23 (-1.55%)

18:10
12/13/17
12/13
18:10
12/13/17
18:10
Hot Stocks
Huntington Bancshares raises prime rate to 4.5% from 4.25% »

Huntington Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.10

-0.2 (-0.79%)

18:06
12/13/17
12/13
18:06
12/13/17
18:06
Hot Stocks
Breaking Hot Stocks news story on Associated Banc-Corp »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBS

UBS

$17.90

0.035 (0.20%)

18:05
12/13/17
12/13
18:05
12/13/17
18:05
Periodicals
UBS Wealth Management president Zeltner close to stepping down, Bloomberg says »

UBS Wealth Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.64

0.06 (0.16%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
Pfizer announces FDA approves IXIFI, a biosimilar to Remicade »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jan

CNP

CenterPoint Energy

$28.40

0.02 (0.07%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
CenterPoint Energy raises quarterly dividend 4% to 27.75c per share »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$11.99

-0.26 (-2.12%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Recommendations
MiMedx analyst commentary at Piper Jaffray »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CE

Celanese

$108.31

1.34 (1.25%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Celanese raises acetyl intermediates products prices »

Raises price on Vinyl…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$57.30

-1.25 (-2.13%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Western Alliance: Sarver to transition from chairman, CEO to exec chairman in Q1 »

Western Alliance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$54.60

-0.9 (-1.62%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
U.S. Bancorp raises prime lending rate to 4.50% from 4.25%, effective Dec 14 »

U.S. Bancorp last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

WBS

Webster Financial

$56.16

-0.73 (-1.28%)

18:00
12/13/17
12/13
18:00
12/13/17
18:00
Hot Stocks
Webster raises prime lending rate to 4.5% from 4.25% »

Webster Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HSBC

HSBC

$51.44

0.89 (1.76%)

17:56
12/13/17
12/13
17:56
12/13/17
17:56
Hot Stocks
Breaking Hot Stocks news story on HSBC »

HSBC raises prime,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$37.59

0.32 (0.86%)

17:47
12/13/17
12/13
17:47
12/13/17
17:47
Hot Stocks
Aqua America names CEO Christopher Franklin as board chairman »

Aqua America announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MSFT

Microsoft

$85.35

-0.23 (-0.27%)

17:38
12/13/17
12/13
17:38
12/13/17
17:38
Hot Stocks
Microsoft launches new AI-powered search features for Bing »

Microsoft announced in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.